시장보고서
상품코드
1481169

세계의 인플루엔자 치료제 시장

Influenza Medication

발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 196 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인플루엔자 치료제 세계 시장은 2030년까지 20억 달러에 달할 전망

2023년에 17억 달러로 추정되는 인플루엔자 치료제 세계 시장은 분석기간 2023-2030년에 CAGR 1.9%로 성장하여 2030년에는 20억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 자나미비르는 CAGR 1.2%를 기록하고, 분석기간 종료시에는 1억 2,390만 달러에 달할 것으로 예측됩니다. 오셀타미비르 부문은 향후 7년간 CAGR이 2.3%로 예측됩니다.

미국 시장은 4억 7,420만 달러로 추정, 중국은 CAGR 2.7%로 성장할 것으로 예측

미국의 인플루엔자 치료제 시장은 2023년에는 4억 7,420만 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2023년부터 2030년까지 분석기간 동안 CAGR 2.7%로 성장하여 2030년까지 3억 5,930만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지리적 시장으로는 일본과 캐나다가 있고, 각각 2023년부터 2030년까지 1.4%와 1.7%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 1.5%로 성장할 것으로 예측됩니다. 호주, 인도, 한국 등의 국가가 견인하는 아시아태평양의 시장은 2030년까지 2억 4,330만 달러에 달할 것으로 예측됩니다.

2024년 매력적인 새로운 보고서 기능 소개

인플루언서 참여 통계에 대한 풀 액세스

디지털 아카이브와 "MarketGlass" 조사 플랫폼에 무료로 액세스할 수 있습니다. 당사의 독자적인 MarketGlass 플랫폼은 전 세계 전문가들의 창의성과 시장 지식을 통합적이고 협력적으로 발휘할 수 있도록 지원합니다. 당사의 최첨단 도구는 시장 진입자의 프라이버시와 신원을 보호하면서 세계적 수준의 시장 전망을 제공합니다. 보고서의 수치, 통계 및 시장 설명은 이 분야의 전문가와 영향력 있는 사람들이 공유한 완전히 선별된 인사이트를 기반으로 합니다.

실시간 데이터 시뮬레이터 도구와 맞춤형 보고서 작성 기능을 갖춘 인터랙티브 설문 조사에 참여할 수 있습니다.

기업 간 스마트한 의견 교환을 위한 피어 협업 인터랙티브 플랫폼에 대한 풀 클라이언트 액세스

1년간 무료 보고서 업데이트

주요 기업의 세계 시장 점유율을 포함한 경쟁 커버리지

여러 지역에 걸친 기업의 시장 입지 분석(호조/활발/틈새/마이너)

전문가/인플루언서 인터뷰, 팟캐스트, 언론 발표, 이벤트 기조연설 유튜브 동영상에 대한 접근성

2024년 세계 경제에 대한 기대

통화 긴축과 이에 따른 금리 상승으로 인한 지정학적, 경제적 불안정성이 2024년 격동적인 상황을 만들어 낼 것으로 보입니다. 중동의 적대 행위와 점점 더 잦아지는 기후 재해 등 여러 요인들이 회복의 길에 계속 압력을 가할 것으로 예상됩니다. 위험요인이 있는 반면, 디플레이션 조짐이 강해지고, 완고한 인플레이션에 대한 불안감이 완화되고, 공급망이 정상화되고, 에너지 비용 변동에도 불구하고 물가가 완만하게 상승하는 등 몇 가지 긍정적인 요인도 나타나고 있습니다. 인도와 미국을 비롯한 G21 국가들의 선거는 자본 흐름과 투자 전략에 영향을 미칠 수 있습니다. 인도가 글로벌 투자처로 주목받고 있는 가운데, 미국에 기반을 둔 하이테크 기업들은 역동적인 인재와 자본 생태계에 힘입어 계속 우위를 점할 것으로 보입니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 둔화되긴 했지만 여전히 견고하고 규제 환경이 잘 정비되어 있어 높은 성장 잠재력을 추구하는 투자자들에게 여전히 매력적일 것으로 보입니다. 유럽은 긴축정책과 경기침체 리스크와의 싸움이 계속되고 있으며, 영국은 2024년 경기침체 리스크가 가장 높은 국가로 가장 어려운 전망을 보이고 있습니다. 중국은 정부 지출과 개인 소비 개선에 힘입어 성장세를 이어갈 것으로 예상되는 와일드카드가 될 것입니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 도전을 동시에 가져다 줄 것으로 보입니다. 변동성을 성장의 촉매제로 받아들이고, 민첩한 투자 판단과 전략적 선견지명이 생존을 위한 핵심 요소로 작용할 것입니다.

조사 대상 기업 사례(총 46건)

  • Biostar Pharmaceuticals
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Natco Pharma Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 24.06.07

Global Influenza Medication Market to Reach $2 Billion by 2030

The global market for Influenza Medication estimated at US$1.7 Billion in the year 2023, is expected to reach US$2 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2023-2030. Zanamivir, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$123.9 Million by the end of the analysis period. Growth in the Oseltamivir segment is estimated at 2.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $474.2 Million, While China is Forecast to Grow at 2.7% CAGR

The Influenza Medication market in the U.S. is estimated at US$474.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$359.3 Million by the year 2030 trailing a CAGR of 2.7% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.4% and 1.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$243.3 Million by the year 2030.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 46 Featured) -

  • Biostar Pharmaceuticals
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Natco Pharma Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Influenza Medication - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Influenza Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Influenza Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Influenza Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Zanamivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Zanamivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Zanamivir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Oseltamivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Oseltamivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Oseltamivir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Peramivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Peramivir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Peramivir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Amantadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Amantadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Amantadine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Rimantadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Rimantadine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Rimantadine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Influenza Medication Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Influenza Medication by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Influenza Medication by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Influenza Medication by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Medication by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Influenza Medication by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Influenza Medication by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Influenza Medication by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Influenza Medication by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Influenza Medication by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Influenza Medication by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Influenza Medication by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Influenza Medication by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Influenza Medication Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Influenza Medication by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Influenza Medication by Product - Percentage Breakdown of Value Sales for Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and Other Products for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Influenza Medication by Distribution Channel - Hospitals, Clinics and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Influenza Medication by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Clinics and Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제